Bipolar Disorder Drug Sales in 5EU Reached USD 773.8 Mln in 2014, States GlobalData in Its In-demand Report Published at MarketPublishers.com21 Jun 2016 • by Natalie Aster
LONDON – The bipolar disorder marketplace is broadly genericized, with additional major brands expected to counter patent expirations or expiries of data exclusivity period in the offing. The size of the bipolar disorder market is set to contract considerably through 2024, fuelled mainly by the generic erosion of Otsuka’s antipsychotic medicine Abilify, the top-selling product for bipolar disorder as of 2014. The adoption of new atypical antipsychotic medications will likely be a key growth driver in the forthcoming years, as these medicines offer clinical benefits that are poised to drive such strong uptake. Nevertheless, sales of these products will likely be restrained by the ongoing use of entrenched generic products. There are presently only 2 agents in phase III clinical trials, which signifies that bipolar disorder is set to remain an area of high unmet need in the foreseeable future.
The sales of drugs for bipolar disorder in the 5EU amounted to USD 773.8 million as of 2014. The generic erosion of Otsuka’s Abilify is anticipated to lead to an initial shrinking in the market size till 2016. Meantime, beginning from 2017, the market is poised to gain traction, fuelled by the uptake of pipeline agents coupled with surging rates of diagnosis and treatment of the disease across the 5EU. The sector’s growth is projected to slow by end-2024 due to the established uptake of both generic drugs and pipeline products in the marketplace.
Topical research report “Bipolar Disorder - 5EU Drug Forecast and Market Analysis to 2024” created by GlobalData provides a detailed guide to the market across 5EU, namely France, Italy, Germany, the UK and Spain. It offers an overview of the disease, detailing epidemiology, etiology, diagnosis, symptoms, pathology and treatment guidelines. It also includes insights into the competitive scenario. The report includes granular information on the top drugs in 5EU, comprising a description of products, efficacy and safety profiles along with a SWOT analysis. The study provides sales forecast for the top drugs in 5EU to 2024. It canvasses the influence of major events and also limelights the drivers and limiters affecting the bipolar disorder sector in the countries in question.
More reports by the publisher can be found at GlobalData page.